Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

3 terminated/withdrawn out of 21 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 15 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
12(63.2%)
Phase 2
6(31.6%)
N/A
1(5.3%)
19Total
Phase 1(12)
Phase 2(6)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT02022514Phase 2Completed

Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.

Role: lead

NCT02687646Phase 1Completed

Clinical Trial With MSC for Graft Versus Host Disease Treatment

Role: lead

NCT01745783Phase 1Completed

Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis

Role: lead

NCT02290886Phase 1Completed

A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral

Role: lead

NCT01765244Phase 1Completed

Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment

Role: lead

NCT04630288Unknown

Safety and Efficacy of Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndrome

Role: lead

NCT02033278Phase 2Terminated

Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.

Role: lead

NCT02290041Phase 1Completed

Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response

Role: lead

NCT02287974Phase 1Terminated

Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin

Role: lead

NCT01745744Phase 2Completed

Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.

Role: lead

NCT01751243Phase 1Withdrawn

Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies

Role: lead

NCT02292628Phase 1Completed

Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence

Role: lead

NCT02968589Not ApplicableUnknown

@ctiveHip Tele-rehabilitation System

Role: collaborator

NCT01222039Phase 1Completed

Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease.

Role: lead

NCT01408381Phase 2Completed

Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Non-diabetic Patients With Critical Limb Ischemia (CLI).

Role: lead

NCT00987363Phase 1Completed

Intraarterial Infusion of Autologous Bone Marrow in Diabetic Patients With Chronic Ischemia of Lower Limbs (CLI) no Revascularization

Role: lead

NCT01745731Phase 2Completed

Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration

Role: lead

NCT02573272Unknown

Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

Role: lead

NCT01056471Phase 1Completed

Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis

Role: lead

NCT01257776Phase 1Completed

Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients

Role: lead